Five Oceans Advisors Has $819,000 Stock Position in Novartis AG (NYSE:NVS)

Five Oceans Advisors increased its stake in shares of Novartis AG (NYSE:NVS) by 39.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,343 shares of the company’s stock after acquiring an additional 2,087 shares during the quarter. Five Oceans Advisors’ holdings in Novartis were worth $819,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of NVS. Nexus Investment Management ULC bought a new stake in shares of Novartis during the first quarter valued at approximately $25,000. Raiffeisen Bank International AG bought a new position in Novartis in the fourth quarter worth $25,000. Human Investing LLC acquired a new stake in Novartis during the fourth quarter worth $25,000. Union Bancaire Privee UBP SA bought a new stake in Novartis in the 4th quarter valued at $27,000. Finally, Park Square Financial Group LLC bought a new stake in Novartis in the 4th quarter valued at $30,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Price Performance

NYSE:NVS opened at $118.14 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The firm has a market cap of $249.57 billion, a PE ratio of 20.09, a price-to-earnings-growth ratio of 1.70 and a beta of 0.59. Novartis AG has a 12 month low of $96.06 and a 12 month high of $120.92. The company’s 50-day moving average price is $112.17 and its two-hundred day moving average price is $107.20.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.16. The company had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $12.92 billion. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Novartis’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. On average, equities analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas upgraded shares of Novartis to a “strong-buy” rating in a research report on Tuesday, April 15th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.